Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Epithelial Ovarian Cancer
Interventions
BIOLOGICAL

MUC1 Dendritic Cell Vaccine (Cvac)

"The recommended dosing regimen for CAN-003X was every 4 weeks for the first 3 doses and then every 12 weeks for 3 doses, for a total of 6 doses over 44 weeks (Regimen A, applicable to CAN-003 observational Standard of Care patients and CAN-003 Cvac patients that have progressed prior to the fourth dose of Cvac).~Participants who received more than 3 doses of Cvac in CAN-003 continued with the CAN-003 dosing schedule (Regimen B; Cvac every 4 weeks for a total of 7 doses and then every 8 weeks for 3 doses, for a total of 10 doses over approximately 48 weeks)."

Trial Locations (6)

4120

Greenslopes Private Hospital, Greenslopes

33487

Collaborative Research Group, Boca Raton

46202

Indiana University Simon Cancer Center, Indianapolis

92037

Scripps Cancer Center, La Jolla

94904

Marin Cancer Care, Inc., Greenbrae

98109

University of Washington Medical Center, Seattle

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Prima BioMed Ltd

INDUSTRY